Grant: Alliance Grants
The University of British Columbia
$25,000.00
Point-of-Care Molecular Assay and Smartphone-based Device Toward Early Diagnosis of Liver Fibrosis
FY 2023-24
Summary
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the world, affecting 25% of people globally. The disease increases the risk of cardiovascular disease and may lead to liver fibrosis, then cirrhosis, and ultimately liver failure or cancer. NAFLD affects 7 million Canadians, and a 65% increase in advanced cases is expected by 2030. Unfortunately, liver disease is difficult to diagnosis until it is too late for effective treatment. Recent advances have found biomarkers to support early diagnosis of liver disease at the fibrosis stage, but these methods require specialized facilities and personnel, making them inaccessible to persons in rural and remote communities.In partnership with international collaborators, we will develop a molecular diagnostic test for the early detection of liver fibrosis using a portable, low-cost, smartphone-based device. This test will detect up to three biomarkers of fibrosis using a process of energy transfer between a luminescent terbium complex and fluorescent quantum dot nanoparticles. This approach is selected because it is well suited to using a smartphone camera as a measurement device and minimal processing of blood samples, making it a good match to a point-of-care setting. The proposed technology will enable more inclusive and equitable health care in Canada, and will help combat the growing the morbidity and mortality from liver disease in Canada and worldwide.
Program
Alliance Grants
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
591166-2023
Name nom
Algar, Russ WR
Department département
Chemistry
Organization id
2
Institution établissement
The University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2023
Award amount
25000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
3504
Research subject group en
Analytical chemistry
Research subject group fr
Bioanalytical chemistry
Research subject en
Chimie analytique
Research subject fr
Chimie bioanalytique
Application title
Point-of-Care Molecular Assay and Smartphone-based Device Toward Early Diagnosis of Liver Fibrosis
Keyword
Fluorescence; Forster resonance energy transfer; Immunoassay; Liver disease; Luminescent lanthanide complexes; Molecular diagnostics; Point of care diagnostics; Quantum dots; Smartphone
Application summary
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the world, affecting 25% of people globally. The disease increases the risk of cardiovascular disease and may lead to liver fibrosis, then cirrhosis, and ultimately liver failure or cancer. NAFLD affects 7 million Canadians, and a 65% increase in advanced cases is expected by 2030. Unfortunately, liver disease is difficult to diagnosis until it is too late for effective treatment. Recent advances have found biomarkers to support early diagnosis of liver disease at the fibrosis stage, but these methods require specialized facilities and personnel, making them inaccessible to persons in rural and remote communities.In partnership with international collaborators, we will develop a molecular diagnostic test for the early detection of liver fibrosis using a portable, low-cost, smartphone-based device. This test will detect up to three biomarkers of fibrosis using a process of energy transfer between a luminescent terbium complex and fluorescent quantum dot nanoparticles. This approach is selected because it is well suited to using a smartphone camera as a measurement device and minimal processing of blood samples, making it a good match to a point-of-care setting. The proposed technology will enable more inclusive and equitable health care in Canada, and will help combat the growing the morbidity and mortality from liver disease in Canada and worldwide.